Rebamipide
Based on 6 publication(s) in Google Scholar
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.74%
- CAS No.: 90098-04-7
- Formule: C19H15ClN2O4
- Masse moléculaire:370.79
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Highly Selective Activators Library
HY-L159
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Rebamipide
More
Customer Validation & Images
-
Histological Imaging/Staining
-
WB
-
IF
Activité biologique
|
COX-2 |
Rebamipide (1.4, 2.7, 5.4 mM; 24 h) inhibits proliferation of gastric cancer cell[1].
Rebamipide (5.4 mM; 30 min) activates Smad signaling pathway in AGS cells[1].
Rebamipide (5.4 mM; 3 h) induces the expression of Cdk inhibitor p21 in AGS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AGS cells
-
Concentration:1.4, 2.7, 5.4 mM
-
Incubation Time:24 h
-
Result:Significant decreased in cell proliferation in a concentration-dependent manner.
-
Cell Line:AGS cells
-
Concentration:5.4 mM
-
Incubation Time:30 min or 3 h
-
Result:Significantly increased phosphorylation of Smad2/3 by 1.2-fold when at 30 min and formation of Smad2/3-Smad4 complex by 1.4-fold.
Upregulated expression of p21 protein by 2.5-fold when at 3 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Specific pathogen-free male Sprague-Dawley rats (200-230 g; 7-week-old)[2].
-
Dosage:5, 15, 50 mg/kg
-
Administration:Oral administration; once daily for 14 days.
-
Result:Increased the level of COX-2 immunoreactivity and PGE2 in a dose-dependent manner. (PGE2 is implicated in protection of gastric mucosa from various insults and acceleration of gastric wound healing).
Inhibited intragastric HCl administration-induced gastric mucosal bleeding and erosion.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 90098-04-7
-
Appearance Solid
-
Masse moléculaire 370.79
-
Formule C19H15ClN2O4
-
Color White to off-white
-
SMILES
OC(C(NC(C1=CC=C(Cl)C=C1)=O)CC(C2=CC=CC=C2N3)=CC3=O)=O
-
Synonyms
OPC12759; Proamipide
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy. [Abstract]2021 Jan;38:101774. PMID: 33152664 -
Pharmacol Res
Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling. [Abstract]2024 Nov 27:107525. PMID: 39613121 -
J Nutr Biochem
Jujuboside A ameliorates glomerular podocytes lipotoxicity in diabetic mice by YY1-mediated promotion of intracellular cholesterol transport and efflux. [Abstract]2025 Dec 13:150:110231. PMID: 41397601 -
Int J Mol Sci
2025 Oct 18;26(20):10132. PMID: 41155424
Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132. [Abstract]
H&E staining of skin sections revealed that rebamipide treatment increased dermal thickness, hair bulb size, and hair shaft elongation compared to the control group. Ki67 immunofluorescent staining revealed enhanced cellular proliferation in the hair bulbs of Rebamipide-treated mice. Nuclei were stained with DAPI.
Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132. [Abstract]
Western blot analysis of autophagy-related proteins in telogen-phase skin of mice treated with 3% Rebamipide for 7 days.
Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132. [Abstract]
Immunofluorescent staining of LC3 in the dermal white adipose tissue (dWAT) layer of the dorsal skin treated with 3% Rebamipide for 7 days to assess autophagy activation.
-
Exp Neurol
Peroxisome proliferator-activated receptor-γ ameliorates neuronal ferroptosis after traumatic brain injury in mice by inhibiting cyclooxygenase-2. [Abstract]2022 Apr 29;354:114100. PMID: 35490721 -
Mol Immunol
Thymoquinone, extract from Nigella sativa seeds, protects human skin keratinocytes against UVA-irradiated oxidative stress, inflammation and mitochondrial dysfunction. [Abstract]2021 Jul:135:21-27. PMID: 33857815
Solvant et solubilité
DMSO : 25 mg/mL (67.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.74 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (26.97 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6969 mL | 13.4847 mL | 26.9694 mL | 67.4236 mL |
| 5 mM | 0.5394 mL | 2.6969 mL | 5.3939 mL | 13.4847 mL | |
| 10 mM | 0.2697 mL | 1.3485 mL | 2.6969 mL | 6.7424 mL | |
| 15 mM | 0.1798 mL | 0.8990 mL | 1.7980 mL | 4.4949 mL | |
| 20 mM | 0.1348 mL | 0.6742 mL | 1.3485 mL | 3.3712 mL | |
| 25 mM | 0.1079 mL | 0.5394 mL | 1.0788 mL | 2.6969 mL | |
| 30 mM | 0.0899 mL | 0.4495 mL | 0.8990 mL | 2.2475 mL | |
| 40 mM | 0.0674 mL | 0.3371 mL | 0.6742 mL | 1.6856 mL | |
| 50 mM | 0.0539 mL | 0.2697 mL | 0.5394 mL | 1.3485 mL | |
| 60 mM | 0.0449 mL | 0.2247 mL | 0.4495 mL | 1.1237 mL |
Rebamipide Related Classifications
HY-B0360 Related Classifications
Powered by Bioz